Actimed appoints Dr. Anders Ullman to its board

The UK clinical-stage drug developer said the former Sobi R&D and medical chief joins as it advances programmes in cancer cachexia, obesity and other muscle-wasting disorders.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.